Genome-Wide Association Study for Femoral Neck Bone Geometry

Lan-Juan Zhao,1,4 Xiao-Gang Liu,3 Yao-Zhong Liu,4 Yong-Jun Liu,4 Christopher J Papasian,4 Bao-Yong Sha,1,2 Feng Pan,3 Yan-Fang Guo,3 Liang Wang,3 Han Yan,3 Dong-Hai Xiong,4 Zi-Hui Tang,2 Tie-Lin Yang,3 Xiang-Ding Chen,2 Yan Guo,3 Jian Li,4 Hui Shen,4 Feng Zhang,3 Shu-Feng Lei,2,4 Robert R Recker,1 and Hong-Wen Deng2,3,4

1Osteoporosis Research Center, Creighton University Medical Center, Omaha, NE, USA
2Laboratory of Molecular and Statistical Genetics, College of Life Sciences Hunan Normal University, Changsha, Hunan 410081, Peoples Republic of China
3Key Laboratory of Biomedical Information Engineering, Ministry of Education and Institute of Molecular Genetics, School of Life Science and Technology, Xi’an Jiaotong University, Xi’an, Shanxi 710049, Peoples Republic of China
4School of Medicine, University of Missouri–Kansas City, Kansas City, MO, USA

ABSTRACT
Poor femoral neck bone geometry at the femur is an important risk factor for hip fracture. We conducted a genome-wide association study (GWAS) of femoral neck bone geometry, examining approximately 379,000 eligible single-nucleotide polymorphisms (SNPs) in 1000 Caucasians. A common genetic variant, rs7430431 in the receptor transporting protein 3 (RTP3) gene, was identified in strong association with the buckling ratio (BR, \(P = 1.6 \times 10^{-7}\)), an index of bone structural instability, and with femoral cortical thickness (CT, \(P = 1.9 \times 10^{-5}\)). The RTP3 gene is located in 3p21.31, a region that we found to be linked with CT (LOD = 2.19, \(P = 6.0 \times 10^{-4}\)) in 3998 individuals from 434 pedigrees. The replication analyses in 1488 independent Caucasians and 2118 Chinese confirmed the association of rs7430431 to BR and CT (combined \(P = 7.0 \times 10^{-3}\) for BR and \(P = 1.4 \times 10^{-2}\) for CT). In addition, 350 hip fracture patients and 350 healthy control individuals were genotyped to assess the association of the RTP3 gene with the risk of hip fracture. Significant association between a nearby common SNP, rs10514713 of the RTP3 gene, and hip fracture (\(P = 1.0 \times 10^{-4}\)) was found. Our observations suggest that RTP3 may be a novel candidate gene for femoral neck bone geometry.

KEY WORDS: GENOME-WIDE ASSOCIATION; FEMORAL NECK BONE GEOMETRY; BONE FRACTURE; RTP3

Introduction

Osteoporosis is a skeletal disorder that is characterized by low bone strength and an increased risk of bone fracture. In the United States, osteoporosis leads to 5.2 million fractures per decade.1 Among fractures at various skeletal sites, hip fracture is the most important owing to its high prevalence,2 high mortality and morbidity,3 and excessive therapeutic cost.4,5 The direct cost for hip fracture in the United States was around $13.6 billion in 2005,6 and this expenditure is expected to increase substantially owing to the population aging. An important risk factor for hip fracture is reduced femoral neck bone geometry at the proximal femur,7 which is largely determined by low bone mineral density (BMD) and poor femoral neck (FN) bone geometry.8,9 Prospective determination of FN geometric parameters has significant potential to improve the prediction of hip fracture substantially.10–12

FN bone geometry is under strong genetic control.13–15 Previous whole-genome linkage studies have identified several chromosomal regions linked to FN geometry.13,15,16 These linkage findings were inconclusive, however, requiring further fine mapping studies because they identified relatively wide genomic regions that typically contain hundreds of genes. Although several candidate genes have been suggested by a small number of association studies of human femoral geometry,17–21 our current knowledge of genetic factors underlying femoral geometry is relatively superficial.

Genome-wide association study (GWAS) has been used by several research groups to successfully identify genetic factors for a number of complex disorders.22–25 Currently, this approach...
has been regarded as one of the most efficient and feasible methods available to locate genes for complex diseases. Recently, Kiel and colleagues conducted a pilot GWAS for FN bone geometry parameters using the Affymetrix 100K SNP GeneChip. Although several interesting regions were identified in that study, some important genes may have escaped detection owing to the relatively low coverage of the 100K Affymetrix GeneChip. To improve our understanding of the genetic basis of femoral bone geometry, we performed a GWAS using highly dense Affymetrix 500K SNP arrays in 1000 Caucasian subjects. We identified a novel gene, RTP3 (receptor transporting protein 3), associated with two indices of FN bone geometry. The gene’s importance to bone strength and osteoporosis was assessed and confirmed by replication in independent Caucasian and Chinese samples.

Materials and Methods

Subjects and measurements

The study was approved by the institutional review boards of all involved institutions. Signed informed-consent documents were obtained from all study participants before they entered the study.

We first performed a GWAS (stage 1) in 1000 unrelated Caucasian subjects for genes/regions important for FN bone geometry. The most significant gene identified in stage 1 was further studied in three additional unrelated Caucasian and Chinese Han samples (stage 2). All samples studied, in both stage 1 and stage 2, are independent. Table 1 presents basic characteristics of the studied samples, with detailed information as follows:

Caucasian GWAS sample and independent Caucasian sample for within-ethnic group replication study

In stage 1, for the GWAS, 1000 unrelated samples were identified from our established and expanding genetic repertoire currently containing more than 6000 subjects. In stage 2, 1488 unrelated samples were further selected from the remainder of our established samples. All the chosen subjects were unrelated U.S. Caucasians of European origin. Here, unrelated means there are no family links among other subjects in the sample. The subjects were recruited for genetic research by advertising. In the recruitment, individuals with chronic diseases and conditions that potentially might affect bone metabolism were excluded. These diseases/conditions included chronic disorders involving vital organs (e.g., heart, lung, liver, kidney, and brain), serious metabolic diseases (e.g., diabetes, hypo- and hyperparathyroidism, hyperthyroidism, etc.), other skeletal diseases (e.g., Paget disease, osteogenesis imperfecta, rheumatoid arthritis, etc.), chronic use of drugs affecting bone metabolism (e.g., hormone-replacement therapy, corticosteroid therapy, anticonvulsant drugs), and malnutrition conditions (e.g., chronic diarrhea, chronic ulcerative colitis, etc.). In addition, subjects taking anti-bone-resorptive or bone anabolic agents/drugs, such as bisphosphonates, were excluded from this study. The purpose of these exclusion criteria was to minimize the effects of environmental and therapeutic factors to influence the skeletal system. Minimizing the influence of these variables should provide for relative augmentation of the effects of genetic factors in our study sample, thereby improving our study design through increased statistical power for detecting these genetic factors.

Areal BMD (g/cm²) and region area (cm²) of FN were measured using Hologic machines (Hologic, Inc., Bedford, MA, USA). The machines were calibrated daily. The coefficient of variation (CV) values of the DXA measurements for FN BMD and region area were 1.87% and 1.97%, respectively.

Using DXA-derived FN BMD and region area, we estimated two FN geometric variables. The algorithm and the underlying assumptions regarding the geometry and structure of FN were elaborated earlier. Briefly, the method assumes that (1) bone within the FN region has the configuration of a uniform circular cylinder, (2) 60% of the measured bone mass is cortical (i.e., $t _{c} = 0.6$), and (3) the effective BMD in fully mineralized bone tissue is 1.05 g/cm³ (i.e., $\rho _{mn} = 1.05$ g/cm³). All these assumptions were substantiated as good approximations.

The estimated FN geometric variables are $CT$ (cortical thickness) and $BR$ (buckling ratio)—an index for bone structural stability. They are computed as follows:

$$BR = \frac{W/2}{CT}$$

$$CT = \frac{W - ED}{2}$$

Table 1. Characteristics of the Study Subjects

| Stage 1: Caucasians | Stage 2: Caucasians | Stage 2: Chinese | Stage 2: Chinese |
|---------------------|---------------------|------------------|------------------|
| GWAS unrelated       | Unrelated bone      | Unrelated bone   | Hip fracture sample |
| Caucasians           | geometry sample     | geometry sample  | Case | Control |
| Number               | 987                 | 1488             | 2118             | 350   | 350     |
| Sex ratio (M/F)      | 496/491             | 660/828          | 1119/999         | 124/226 | 173/177 |
| Age (years)          | 50.35 (18.31)       | 54.97 (16.77)    | 28.17 (8.31)     | 69.35 (7.41) | 69.54 (6.09) |
| Weight (kg)          | 80.14 (17.80)       | 80.93 (18.01)    | 57.09 (9.46)     | 59.15 (12.05) | 59.61 (10.84) |
| Height (cm)          | 170.33 (9.74)       | 170.32 (9.77)    | 164.10 (1.82)    | 162.84 (8.31) | 159.41 (9.20) |
| Buckling ratio       | 12.01 (2.74)        | 12.79 (2.63)     | 10.60 (1.82)     | —     | —       |
| Cortical thickness (cm) | 0.16 (0.03)      | 0.15 (0.03)      | 0.16 (0.02)      | —     | —       |

Note: Data presented are unadjusted means (SD).
where

\[ ED = 2 \cdot \sqrt{\frac{W}{2}^2 - \frac{\text{CSA}}{\pi}} \]

where \(W\) is the FN periosteal diameter and can be approximated by dividing the region area of FN by the width of the region of interest (in Hologic DXA systems, the width of the FN region is standardized at 1.5 cm).\(^{(21)}\) CSA (cross-sectional area) is calculated as

\[ \text{CSA} = \frac{\text{BMD} \times W}{\rho_m} \]

**Chinese unrelated bone geometry sample**

The 2118 unrelated Chinese subjects were healthy Chinese Han adults living in Changsha City. As with the Caucasian samples, Chinese subjects with chronic disorders involving vital organs, serious metabolic diseases, other skeletal diseases, chronic use of drugs affecting bone metabolism, and malnutrition conditions were excluded from the study. Areal BMD (g/cm\(^2\)) and region area (cm\(^2\)) of FN were measured using Hologic 4500W machines (Hologic, Inc., Bedford, MA, USA) under the same strict protocols used with the Caucasian sample. The CV of the DXA measurements for FN BMD and region area were 3.43% and 2.33%, respectively. BR and CT were estimated under the same method as those used for the Caucasians.

**Chinese unrelated hip fracture sample**

The Chinese unrelated hip fracture samples were recruited from Xi’an City or neighboring areas, which is more than 1000 km from Changsha City. It therefore was an independent Chinese cohort. The sample consisted of 350 patients with osteoporotic hip fracture (including 124 males and 226 females) and 350 healthy normal control individuals (including 173 males and 177 females). Affected individuals with low-trauma hip fracture were recruited between 2004 and 2007 from the affiliated hospitals and their associated clinics of Xi’an Jiaotong University. Inclusion criteria for cases were (1) age at hip fracture ≥ 55 years for both male and female subjects and all women enrolled were postmenopausal, (2) minimal trauma fractures, usually owing to falls from standing height or less, (3) fracture site at FN or intertrochanter, and (4) hip fracture was identified through diagnosis of orthopedic surgeons/radiologists according to radiologic reports or X-rays. Patients with pathologic fractures, high-trauma fractures (such as motor vehicle accident), and late complications of fractures of the proximal femur requiring a second intervention were excluded. Control subjects were enrolled with the following inclusion criteria: (1) age at exam ≥ 60 years and (2) exclusion of subjects with chronic diseases and conditions that potentially might affect bone mass, structure, or metabolism (the exclusion criteria are the same as those adopted in recruitment of Caucasian subjects).

**Genotyping**

**Caucasian GWAS sample**

Genomic DNA was extracted from whole human blood using a commercial isolation kit (Gentra Systems, Minneapolis, MN, USA) following the protocols detailed in the kit. Genotyping with the Affymetrix Mapping 250K Nsp and Affymetrix Mapping 250K Sty arrays was performed using the standard protocol recommended by the manufacturer. Fluorescence intensities were quantified using Affymetrix Array Scanner 30007G. Data management and analyses were performed using the Affymetrix GeneChip Operating System. Genotyping calls were determined from the fluorescent intensities using the dynamic modeling (DM) algorithm with a 0.33 \(P\)-value setting\(^{(33)}\) as well as the Bayesian robust linear model with Mahalanobis distance (B-RLMM) algorithm.\(^{(34)}\) DM calls were used for quality control, whereas the B-RLMM calls were used for all subsequent data analyses. B-RLMM clustering was performed with 94 samples per cluster.

Following an Affymetrix guideline, we set a standard for the minimum DM call rate at 93% for a sample, considering all the single-nucleotide polymorphisms (SNPs) in the two arrays, the 250K Nsp and 250K Sty arrays. Eventually, 997 subjects who had at least one array (Nsp or Sty) reaching a 93% call rate were retained. Because of missing data for bone geometry phenotypes among the 997 subjects, the effective sample size for the GWAS was 987 for both BR and CT. The average call rate for the 987 analyzed subjects reached greater than 95%. Of the initial full set of 500,568 SNPs, we discarded 32,961 SNPs with SNP-wise call rate greater than 95%, 36,965 SNPs with allele frequencies deviating from Hardy-Weinberg equilibrium (HWE, \(P < .001\)), and 51,323 SNPs with minor allele frequency (MAF) less than 1%. Therefore, the final SNP set for the GWAS scan contained 379,319 SNPs, yielding a genomic marker spacing of approximately 7.9 kb on average.

**Caucasian bone geometry sample**

Genomic DNA extraction and quality control procedures are the same as those used for the GWAS sample. Genotyping of the interesting SNPs identified from the GWAS in the Caucasian unrelated sample was performed by KBioscience (Herts, UK) using the technology of competitive allele-specific PCR (KASPar), which is detailed at the company’s Web site (www.kbioscience.co.uk). The replication rate (duplicate concordance rate) was 99.7% for genotyping, and the average call rate was 97.8%.

**Chinese bone geometry sample**

Genomic DNA was isolated from whole blood using the phenol-chloroform extraction method. The concentration of DNA was quantified using a DU530 UV/VIS Spectrophotometer (Beckman Instruments, Fullerton, CA, USA). The same set of SNPs used for the Caucasian bone geometry sample was successfully genotyped in the Chinese bone geometry sample of 2118 subjects. Genotyping was performed using a primer extension method with MALDI-TOF mass spectrometry for multiplexed genotyping of SNPs on a MassARRAY system, as suggested by the
manufacturer (Sequenom, Inc., San Diego, CA, USA) and described by Braun and colleagues.\textsuperscript{35} The replication rate was 99.2%, and the average call rate was 97.2%.

### Chinese Hip Fracture Sample

Genomic DNA extraction methodology was the same as that used with the Chinese bone geometry sample. The 350 hip fracture cases and 350 controls were genotyped using Affymetrix Mapping 250K Nsp and Affymetrix Mapping 250K Sty arrays. The final mean B-RLMM call rate reached a level of 99.02%, and the duplication rate was 99.70%. The discordant genotypes were discarded. Genotypes of interesting SNPs in this cohort were obtained from the Affymetrix 500K chips.

#### Statistical Analyses

In all four group samples (i.e., Caucasian GWAS, Caucasian bone geometry, Chinese bone geometry, and Chinese hip fracture cohorts), HWE was assessed by chi-square analyses. SNPs that did not follow HWE were excluded from further data analyses.

For the stage 1 Caucasian GWAS sample, parameters such as age, \( \text{age}^2 \), sex, \( \text{age} \times \text{sex} \), by-sex interaction, height, and weight were tested for their associations with BR and CT using stepwise regression. Significant (\( P \leq 0.05 \)) terms were included as covariates to adjust the raw BR and CT values for subsequent analyses. For BR, the covariates were age, height, weight, sex, and \( \text{age}^2 \times \text{sex} \). For CT, the covariates were age, weight, and \( \text{age}^2 \). The residuals from a linear model after adjusting for the significant covariates were used as traits in the follow-up data analyses. To minimize possible spurious associations owing to potential population stratification, we used EIGENSTRAT\textsuperscript{36} software in GWAS association analyses. EIGENSTRAT detects and corrects for ancestry information while performing association analyses between phenotypes and genotypes. We used EIGENSTRAT because it can appropriately handle the quantitative data while maintaining sufficient power and robustness.\textsuperscript{36} In the data analyses, the SNPs were coded as 0, 1, and 2 to represent AA, AB, and BB genotypes.

Multiple testing is a perplexing issue in GWAS. Because the Bonferroni correction is considered overly conservative given extensive linkage disequilibrium (LD) among markers, we adopted the GWAS significance threshold of approximately \( 4.2 \times 10^{-7} \) proposed by Lencz and colleagues.\textsuperscript{37} The gene-wise approach used to calculate this threshold took into account recent estimates of the total number of genes in the human genome.

The LD patterns of the most significant gene were analyzed and plotted using the Haploview program\textsuperscript{38} (www.broad.mit.edu/mpg/haploview/). Focused association analyses on certain SNPs and other miscellaneous statistical analyses were performed using software packages SAS (SAS Institute, Inc., Cary, NC, USA) and Minitab (Minitab, Inc., State College, PA, USA), which include descriptive statistics data analysis and multiple regression analysis to screen significant covariates for BR and CT and the normality of the adjusted BR and CT data.

For stage 2 replication analyses of the significant gene, significant parameters (\( P < 0.05 \)) such as age, \( \text{age}^2 \), sex, \( \text{age} \times \text{sex} \), by-sex interaction, height, and weight were used as covariates to adjust for the raw BR and CT values. We used a stepwise regression model to screen significant covariates for each study cohort. Since the effects of these confounding factors on the traits were different in each cohort, different covariates were applied. For unrelated bone geometry Caucasian samples (\( n = 1488 \)), the covariates were age, sex, \( \text{age} 	imes \text{sex} \), weight, and height for BR; weight, \( \text{age}^2 \), \( \text{age} \times \text{sex} \), and \( \text{age} \times \text{sex} \) for CT. For unrelated Chinese bone geometry samples (\( n = 2118 \)), the covariates were age, height, weight, and \( \text{age}^2 \times \text{sex} \) for BR and \( \text{age} \times \text{sex} \), age, and sex for CT. The residuals from a linear regression model after adjusting for the significant covariates were used as traits in the in HelixTree (www.goldenhelix.com/SNP_Variation/HelixTree/index.html). The SNPs were coded numerically with 0 for AA, 1 for AB, and 2 for BB, respectively.

In the replication stage, in order to account for the multiple-testing problem, the SNPSpD method\textsuperscript{39} (http://gump.qimr.edu.au/general/daleN/SNPSpD/) was adopted to infer the effective number of independent tests (\( M_{eff} \)), and the overall significance level was set at 0.05/\( M_{eff} \).

The \( P \) values from cohorts of Chinese and Caucasian samples for bone geometry were combined using Fisher’s method\textsuperscript{40} to quantify the overall evidence for association with bone geometry variation. No cohort/geography adjustment was performed because the tests for Caucasian and Chinese are independent and have the same null hypotheses. In the Chinese hip fracture sample, genotype distributions for SNPs were compared using logistic regression models controlling for sex, age, height, and weight as covariates between the fracture versus nonfracture pooling sample including both males and females.

To detect population stratification that may lead to spurious association results, we used the software Structure 2.2 (http://pritch.bsd.uchicago.edu/software.html) to investigate the potential substructure/stratification of our sample. The Structure 2.2 program uses a Markov chain Monte Carlo (MCMC) algorithm to cluster individuals into different cryptic subpopulations on the basis of multilocus genotype data.\textsuperscript{41} Using the software, we performed independent analyses under an assumption of \( K = 2 \) population strata using 200 unlinked markers in the GWAS unrelated Caucasian cohort and 1000 unlinked markers in the Chinese hip fracture cohort.

### Results

#### GWAS in the Caucasian Sample

Using EIGENSTRAT, which controls for potential population stratification, we performed a genotype association analysis. For all the analyzed SNPs and bone geometry phenotypes, we observed one SNP (rs7430431) beyond the GWAS significant threshold for BR (\( P = 1.61 \times 10^{-7} \); Table 2). This SNP also was found to have a highly suggestive association with FN CT (\( P = 1.92 \times 10^{-8} \)). SNP rs7430431 is located in 3p21.31, a region that we previously found to be linked with CT (LOD = 2.19, \( P = .0006 \)) in 3998 individuals from 434 pedigrees.\textsuperscript{16} The minor allele frequency (MAF) of rs7430431 was 49.4% according to our data and 48.3% according to the HapMap CEU database (see Table 2). The SNP was in HWE and located in the intron of the \( RTP3 \) gene. The \( RTP3 \) gene, which has a total length of approximately 3 kb, contains two exons and one intron. In this
3-kb region, a total of eight SNPs were genotyped. Besides rs7430431, most other SNPs in the region also achieved highly suggestive association with both BR and CT (P ≤ .001; see Table 3). We selected 21 SNPs (see Table 2) within and adjacent to RTP3 to reconstruct the LD block using Haploview in order to further study this gene. Four blocks were reconstructed (Fig. 1). Haplotype data analysis indicated that haplotype block 3, containing rs7430431 has a highly suggestive association with BR (P = 5.76 × 10^{-5}) (see Fig. 1). We also compared adjusted BR and CT values between different genotypes of SNP rs7430431. In our GWAS subjects, as shown in Fig. 2, subjects with the CC genotype had the highest BR (12.54 ± 0.15 cm) and the lowest CT (1.60 ± 0.15 cm), individual of CT genotype had intermediate BR (12.02 ± 0.10 cm) and CT (1.55 ± 0.001 cm), and individuals of the TT genotype had the lowest BR (11.56 ± 0.14 cm) and the highest CT (1.59 ± 0.001 cm). Thus rs7430431 genotypic effects on BR and CT are approximately additive (Fig. 2). In our study subjects, individuals with the CC genotype had, respectively, approximately 8.2% higher BR and 5.0% lower CT than those with the TT genotype, which consistently leads to poor femoral neck bone geometry.

Replication studies in independent Caucasian and Chinese samples

Replication studies confirmed the association of the RTP3 gene to BR, CT, and hip fracture (Table 3). According to the HapMap-HCB (Han Chinese in Beijing) database, the MAF of SNP rs7430431 is less than 5% (4.4%), indicating a significant MAF difference between Chinese and Caucasian samples. In addition to rs7430431, SNP rs10514713 was selected for further analysis in order to ensure high heterozygosity of the SNPs for replication studies and therefore increase statistical power. SNP rs10514713 is in high LD with rs7430431 and is located in the 3’UTR of the RTP3 gene. There was evidence for association between rs7430431 and both BR (P = .020) and CT (P = .020) in an independent sample of 1488 Caucasians. An association was also detected between BR and rs7430431 (P = .040) and rs10514713 (P = .049) (see Table 3) in 2118 unrelated Chinese. A combined association analysis using Fisher’s method showed that rs7430431 was significantly associated with both BR (P = .007) and CT (P = .014) (see Table 3). Further, the direction of this association is the same as that in the original GWAS Caucasian sample; i.e., C-allele carriers had higher BR and lower CT values than T-allele carriers.

We tested two SNPs (SNPs rs10514713 and rs7430431) and two phenotypes (BR and CT) in our replication study. These tests resulted in a multiple-testing problem. In order to adjust for multiple testing, we used the SNPSpD method to set the overall significance level. The Meff for BR and CT phenotypes is 1.357, and the Meff for the two tested SNPs (SNPs rs10514713 and rs7430431) is 1.515. Thus the significant threshold for the replication stage is set at P = .05/(1.357 × 1.515) = 0.024. According to the threshold, most of our nominal significant results (P < .05) in Table 3 survive.

Table 2. Information for the 21 Analyzed SNPs Within and Adjacent to the RTP3 Gene and Their Association Results in GWAS Analysis Using EIGENSTRAT

| SNP ID   | Name    | Position | Gene   | Role     | Allele | MAFb | MAFc | P value for BR | P value for CT |
|----------|---------|----------|--------|----------|--------|------|------|----------------|----------------|
| 1        | rs2269436 | 46462257 | LTF    | Intron G/A | 0.042  | 0.042 | 2.38 × 10^{-1} | 2.87 × 10^{-1} |
| 2        | rs17141154 | 46462271 | LTF    | Intron A/G | 0.167  | 0.167 | 1.74 × 10^{-3} | 6.21 × 10^{-4} |
| 3        | rs17078863 | 46473920 | LTF    | Intron C/T | 0.045  | 0.042 | 5.02 × 10^{-3} | 3.05 × 10^{-1} |
| 4        | rs7629657 | 46474176 | LTF    | Intron T/C | 0.048  | 0.042 | 4.89 × 10^{-1} | 2.95 × 10^{-1} |
| 5        | rs9862388 | 46479320 | LTF    | Intron G/A | 0.300  | 0.267 | 2.38 × 10^{-1} | 2.87 × 10^{-1} |
| 6        | rs1520483 | 46485213 | RTP3   | Promoter T/C | 0.350  | 0.374 | 1.81 × 10^{-4} | 7.14 × 10^{-4} |
| 7        | rs7639243 | 46488981 | LTF    | Promoter A/C | 0.400  | 0.333 | 2.32 × 10^{-1} | 2.21 × 10^{-1} |
| 8        | rs7641783 | 46489276 | RTP3   | Promoter T/C | 0.273  | 0.258 | 4.06 × 10^{-4} | 6.56 × 10^{-5} |
| 9        | rs883739  | 46513022 | RTP3   | Promoter A/C | 0.352  | 0.375 | 4.99 × 10^{-5} | 8.87 × 10^{-5} |
| 10       | rs7430431 | 46516151 | RTP3   | Intron C/T | 0.494  | 0.483 | 1.61 × 10^{-7} | 1.92 × 10^{-6} |
| 11       | rs11130094 | 46516507 | RTP3   | Intron A/G | 0.404  | 0.364 | 1.03 × 10^{-3} | 2.49 × 10^{-4} |
| 12       | rs10514713 | 46518621 | RTP3   | 3’ UTR A/C | 0.380  | 0.381 | 2.68 × 10^{-4} | 3.09 × 10^{-4} |
| 13       | rs7371865 | 46524192 | RTP3   | 3’ UTR A/C | 0.105  | 0.075 | 2.49 × 10^{-1} | 1.93 × 10^{-1} |
| 14       | rs1879328 | 46543161 | LRR2C2 | Intron G/A | 0.167  | 0.140 | 8.10 × 10^{-1} | 8.40 × 10^{-1} |
| 15       | rs6791703 | 46544725 | LRR2C2 | Intron G/T | 0.498  | 0.500 | 8.69 × 10^{-7} | 1.80 × 10^{-4} |
| 16       | rs939421  | 46551085 | LRR2C2 | Intron G/A | 0.300  | 0.225 | 4.90 × 10^{-2} | 1.60 × 10^{-1} |
| 17       | rs11075987 | 46559076 | LRR2C2 | Intron C/A | 0.210  | 0.246 | 7.54 × 10^{-2} | 5.40 × 10^{-2} |
| 18       | rs9703340 | 46559176 | LRR2C2 | Intron T/A | 0.450  | 0.458 | 5.33 × 10^{-7} | 7.70 × 10^{-5} |
| 19       | rs9846026 | 46563817 | LRR2C2 | Intron A/C | 0.100  | 0.078 | 2.86 × 10^{-2} | 3.90 × 10^{-1} |
| 20       | rs9808967 | 46564298 | LRR2C2 | Intron T/A | 0.050  | 0.076 | 3.03 × 10^{-3} | 9.17 × 10^{-2} |
| 21       | rs11919651 | 46568910 | LRR2C2 | Intron C/A | 0.180  | 0.158 | 3.71 × 10^{-2} | 4.60 × 10^{-2} |

Note: The RTP3 gene is located in 3p21.31. MAF = minor allele frequency; BR = buckling ratio; CT = cortical thickness.

The former allele represents the minor allele of each locus.

Minor allele frequency calculated in our own Caucasian sample.

Minor allele frequency reported for Caucasians in the public database such as Hap Map or dbSNP.

P values were calculated using EIGENSTRAT analyses. Significant results at the GWAS level are labeled in bold.
To further assess the relevance of the RTP3 gene to hip fracture risk, we tested the association of the two SNPs with osteoporotic hip fracture in a Chinese sample consisting of 350 hip fracture patients and 350 healthy controls. A significant association was found between SNP rs10514713 (MAF = 42.9%) and hip fracture (P = .001; see Table 3).

Discussion

Our GWAS and follow-up validation/replication studies in independent Caucasian and Chinese samples identified RTP3 as a potential novel gene associated with variation of BR and CT at the FN. BR and CT are geometric variables associated with hip fracture. BR is an index for bone structural instability and is positively associated with hip fracture. CT is proportional to volumetric and areal BMD with the assumption that the bone within the FN region is a uniform circular cylinder. CT is negatively correlated with hip fracture risk. These two geometric measures are highly correlated with one another and have been reported as important predictors of the incidence of hip fracture. In addition to BR and CT, in the current GWAS of 987 unrelated Caucasian subjects using 379,000 SNPs, we also tested other bone geometric measures, such as CSA and...
section modulus. However, none of the SNPs associated with any known genes reached the GWAS significance threshold (4.2 × 10⁻⁷). Since four FN geometry phenotypes are tested in the data analyses and our threshold (4.2 × 10⁻⁷) may need to be adjusted. We did not adopt a more stringent threshold for the following reasons: (1) We are reporting the most significant results, and the results have been replicated in other independent cohorts, especially in hip fracture cohorts. A stringent GWAS threshold will not change our results. (2) The four phenotypes are highly correlated, and a Bonferroni correction will be too conservative for the study. It should be noted that bone geometry phenotypes are dependent on body size and shape.(48) In our study, although height and weight were used as covariates to adjust size variation, the adjustment cannot totally remove the body size and body shape effect. Currently, there is no established appropriate method to correct body size and body shape effect.

The powerful GWAS analyses reported here identified an intronic polymorphism (rs7430431) in the RTP3 gene as an SNP that was significantly associated with BR variations. Since rs7430431 has a low MAF in Chinese samples, we tested rs7430431 plus a nearby common SNP of the RTP3 gene in our replication studies with independent Caucasian and Chinese samples. These replication analyses confirmed the association between the RTP3 gene and BR. Importantly, the relevance of the RTP3 gene to hip fracture risk also was detected in an independent Chinese sample containing 700 subjects. Since association results may be biased by population stratification, we analyzed for potential population stratification for the cohorts using software Structure 2.2.⁴¹ in a GWAS unrelated Caucasian sample and hip fracture sample. All subjects in the two cohorts were tightly clustered together, suggesting no population stratification.

The RTP3 gene is located at 3p21. This genomic region was reported to be linked with CT (LOD = 2.19, P = .0006) in our prior linkage study performed in 3998 individuals from large pedigrees.⁵⁰ CT is an estimate with an assumption that a 60% of cortical mass is uniformly distributed in the femoral neck region. BMD is an estimate of bone mineral uniformly distributed in a region of interest. Since CT and BMD are highly correlated, we also checked the importance of the 3p21 region for BMD variation. A recent meta-analysis of BMD linkages⁴⁹ failed to identify this region as an important quantitative trait locus (QTL). However, some independent linkage studies support the concept that 3p21 is an important region for FN and spine BMD variations.⁵⁰–⁵³ In 155 osteoporotic families containing 654 study individuals, Duncan and colleagues reported that the 3p21 region achieved a suggestive LOD score for FN BMD (LOD = 2.7).⁵⁰ In addition, a study involving nondiabetic twin pairs (in 1094 pedigrees) detected a suggestive LOD score of 2.7 at chromosome 3p21 for spine BMD.⁵²

We referred to other reported GWAS in the bone field to look for support for the association of the RTP3 gene and FN bone geometry. Among them,²⁸–³⁰,⁵⁴–⁵⁷ FN bone geometry results are only reported in the Framingham study,³⁰ which provides strong, independent support for our finding.³⁰ In the National Center for Biotechnology Information (NCBI) dbGaP database (www.ncbi.nlm.nih.gov/sites/entrez?db=gap), two SNPs (SNP9 rs883739 and SNP12 rs10514713 in Table 2) in the RTP3 gene, which are in high LD with rs7430431 (r² = 0.641 between SNP9 rs883739 and SNP10 rs7430431 and r² = 0.638 between SNP12 rs10514713 and SNP10 rs7430431 in HapMap-CEPH), were genotyped in the Framingham 100,000 GWAS. In the Framingham study, both SNPs rs883739 and SNP12 rs10514713 were significantly associated with FN BR (P = .030 and P = .017, respectively) in women.

RTP3 is a novel gene first identified in 2002. Several lines of evidence support the concept that RTP3 may function as a tumor suppressor gene.⁵⁵–⁵⁷ In addition, the RTP3 protein product shares homology with other RTP family members, which have been shown to contribute to functional cell surface expression of olfactory receptors on olfactory neurons. However, in contrast to RTP1 and RTP2, RTP3 is not expressed in olfactory neurons. Therefore, it appears unlikely that RTP3 influences olfaction in a manner similar to that described for other members of the RTP family.⁵⁸ It is unknown whether RTP3 has other biologic functions.

Table 3. Replication Association Results in Stage 2

| dbSNP       | rs7430431 | rs10514713 |
|-------------|-----------|------------|
| Role        | Intron    | 3' UTR     |
| Alleles     | C/T       | A/C        |
| Unrelated bone geometry Caucasian sample (1488) |         |            |
| MAF         | .409      | .335       |
| P value for BR | .020      | .135       |
| P value for CT | .020      | .198       |
| Unrelated Chinese bone geometry sample (2118) |         |            |
| MAF         | .026      | .486       |
| P value for BR | .040      | .049       |
| P value for CT | .098      | .093       |
| Combined Chinese and Caucasians (3606) |         |            |
| P value for BR | .007      | .040       |
| P value for CT | .014      | .092       |
| Unrelated Chinese hip fracture sample (700) |         |            |
| MAF         | .020      | .429       |
| P value for hip fracture | .308      | .001       |

Note: Stage 2 involved a total of 3606 subjects for replication analysis for BR and CT and 700 subjects for analysis for hip fracture. There is no overlap between these samples. P values were one-tailed. The combined P values were obtained based on Fisher’s method.⁶⁰ No cohort/geo-graphy is adjusted. The results with P < .05 are in bold. MAF = minor allele frequency; BR = buckling ratio; CT = cortical thickness.
This is the first study reporting the potential importance of the RTP3 gene to femoral neck bone geometry. However, the mechanism by which it contributes to femoral neck bone geometry and osteoporotic fracture risk is unknown. It has been suggested that RTP3 may interact with FHT (fragile histidine triad gene), which downregulates the SMAD4 (SMAD family member 4) gene. SMAD4 is a transcription corepressor for the ESR1 (estrogen receptor alpha) gene and strongly inhibits the transcription of various downstream genes of estrogen signaling. Further, it has been shown that SMAD4 has direct physical interactions with ESR1 and serves as a common signal transducer in the bone morphogenetic protein (BMP)/transforming growth factor-beta (TGF-β) signaling pathway. Both estrogen signaling and BMP/TGF-β signaling pathways are important for bone development and skeleton morphogenesis. Furthermore, SMAD4 may directly regulate endochondral bone formation, cartilage growth, bone healing, and osteogenesis and long bone development. Taken together, our study suggests that RTP3 may be a novel candidate gene influencing bone geometry variation, potentially via FHT and SMAD4.

Several limitations of our studies need to be mentioned. First, the unrelated Chinese bone geometry sample was much younger than the discovery cohort and other replication samples. In our study, although age was used as a covariate to adjust the raw BR and CT values, the adjustment may not totally eliminate the age-related difference between groups. Therefore, our replication result may suggest that the RTP3 gene is important for femoral neck bone geometry in both young and old population. Second, different genotyping methods were used for different replication studies owing to different genotyping platforms across the cooperative laboratories. Since all the genotyping methods had high call and replication rates, disparity of the genotyping methods should be acceptable. In actuality, it is common to see the issue of varying genotyping methods arise in GWAS replication studies. For example, Luciano and colleagues used KASPar, MALDI-TOF, and Taqman genotyping methods in their replication studies. With the development of genotyping technology, the concordant rate among different genotyping methods (including MALDI-TOF and KASPar) can be as high as 94% and even greater than 99.9%. Third, although the most significant SNP (rs7430431) was consistently associated with BR in all bone geometry replication studies, no evidence of association was detected between rs7430431 and hip fracture. This may be attributable to the low MAF (MAF = 0.02) of this SNP in the Chinese hip fracture sample. The significant association of a nearby common SNP (rs10514713) (MAF = 42.9%) with hip fracture (P = .001) provides supportive evidence for the potential importance of the RTP3 gene to the risk of hip fracture. Fourth, although SNPs rs10514713 and rs7430431 are tested to be important for bone geometry variation, without a functional study, it is difficult to assert their importance. Without further functional study, it is also difficult for us to confirm the importance of RTP3 in bone development at early osteogenesis and its outcomes later in the life. Fifth, our bone geometry estimates, based on the earlier work, relied on the assumptions of FN shape as a uniform circular cylinder. This assumption may not be completely realistic.

In summary, for the first time, our GWAS identified a novel gene, RTP3, significantly associated with bone femoral geometry. The gene’s relevance to hip fractures and femoral neck bone geometry was further replicated and confirmed in independent Caucasian and Chinese samples. Our findings suggest that RTP3 may be a promising candidate gene for osteoporotic fractures in different ethnic groups. Various further analyses, such as replication in other ethnic populations and molecular functional studies, are needed to validate this finding and delineate the mechanism by which this gene influences femoral neck bone geometry and fracture risk.

Disclosures

The authors state that they have no conflicts of interest.

Acknowledgments

Investigators of this work were partially supported by grants from the National Institutes of Health (R01 AR050496-01, R21 AG027110, R01 AG026564, and P50 AR055081), the cancer and smoking disease research bone biology program, a Nebraska tobacco settlement biomedical research development award, and a grant from the State of Nebraska (LB595). The study also benefited from grants from the National Science Foundation of China, the Huo Ying Dong Education Foundation, HuNan Province, Xi’an Jiaotong University, and the Ministry of Education of China.

References

1. Melton LJ III. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res. 2003;18:1139–1141.
2. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761–1767.
3. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int. 2000;11:556–561.
4. Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a worldwide perspective. Osteoporos Int. 1992;2:285–289.
5. Fleurence RL, Iglesias CP, Torgersson DJ. Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. Osteoporos Int. 2006;17:29–40.
6. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22:465–475.
7. Wehren LE, Magaziner J. Hip fracture: risk factors and outcomes. Curr Osteoporos Rep. 2003;1:78–85.
8. Yoshikawa T, Turner CH, Peacock M, et al. Geometric structure of the femoral neck measured using dual-energy X-ray absorptiometry. J Bone Miner Res. 1994;9:1053–1064.
9. Cheng XG, Lowet G, Boonen S, et al. Assessment of the strength of proximal femur in vitro: relationship to femoral bone mineral density and femoral geometry. Bone. 1997;20:213–218.
10. Puukkinen P, Partanen J, Jalovaara P, Jamsa T. Combination of bone mineral density and upper femur geometry improves the prediction of hip fracture. Osteoporos Int. 2004;15:274–280.
11. Crabtree NJ, Kroger H, Martin A, et al. Improving risk assessment: hip geometry, bone mineral distribution and bone strength in hip
fracture cases and controls. The European Prospective Osteoporosis Study. Osteoporos Int. 2002;13:48–54.

12. Kaptoge S, Beck TJ, Reeve J, et al. Prediction of incident hip fracture risk by femur geometry variables measured by hip structural analysis in the study of osteoporotic fractures. J Bone Miner Res. 2008;23:1892–1904.

13. Shen H, Long JR, Xiong DH, et al. Mapping quantitative trait loci for cross-sectional geometry at the femoral neck. J Bone Miner Res. 2005;20:1973–1982.

14. Slemenda CW, Turner CH, Peacock M, et al. The genetics of proximal femur geometry, distribution of bone mass and bone mineral density. Osteoporos Int. 1996;6:178–182.

15. Demissie S, Dupuis J, Cupples LA, Beck TJ, Kiel DP, Karasik D. Proximal hip geometry is linked to several chromosomal regions: genome-wide linkage results from the Framingham Osteoporosis Study. Bone. 2007;40:743–750.

16. Xiong DH, Shen H, Xiao P, et al. Genome-wide scan identified QTLs underlying femoral neck cross-sectional geometry that are novel studied risk factors of osteoporosis. J Bone Miner Res. 2006;21:424–437.

17. Qureshi AM, McGuigan FE, Seymour DG, Hutchinson JD, Reid DM, Ralston SH. Association between COL1A1 Sp1 alleles and femoral neck geometry. Calcif Tissue Int. 2001;69:67–72.

18. Jiang H, Lei SF, Xiao SM, et al. Association and linkage analysis of COL1A1 and AHSG gene polymorphisms with femoral neck bone geometry parameters in both Caucasian and Chinese nuclear families. Acta Pharmacol Singapore. 2007;28:375–381.

19. Xiong DH, Liu YZ, Liu PY, Zhao LJ, Deng HW. Association analysis of estrogen receptor alpha gene polymorphisms with cross-sectional geometry of the femoral neck in Caucasian nuclear families. Osteoporos Int. 2005;16:2113–2122.

20. Moffett SP, Zmuda JM, Oakley J, et al. Tumor necrosis factor-alpha polymorphism, bone strength phenotypes, and the risk of fracture in older women. J Clin Endocrinol Metab. 2005;90:3491–3497.

21. Rivadeneira F, Houwing-Duistermaat JJ, Beck TJ, et al. The influence of an insulin-like growth factor I gene promoter polymorphism on hip bone geometry and the risk of nonvertebral fracture in the elderly: the Rotterdam Study. J Bone Miner Res. 2004;19:1280–1290.

22. McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges: genome-wide association studies in Alzheimer disease. Nat Rev Genet. 2008;9:356–369.

23. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet. 2005;6:95–108.

24. Hu N, Wang C, Hu Y, et al. Genome-wide association study in esophageal cancer using GeneChip mapping 10K array. Cancer Res. 2005;65:2542–2546.

25. Frayling TM. Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet. 2007;8:657–662.

26. Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science. 2007;316:1341–1345.

27. Scuteri A, Sanna S, Chen WM, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet. 2007;3:e115.

28. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med. 2008;358:2355–2365.

29. Richards JB, Rivadeneira F, Inouye M, et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet. 2008;371:1505–1512.

30. Kiel DP, Demissie S, Dupuis J, Lunetta KL, Murabito JM, Karasik D. Genome-wide association with bone mass and geometry in the Framingham Heart Study. BMC Med Genet. 2007;8:514.

31. Duan Y, Beck TJ, Wang XF, Seeman E. Structural and biomechanical basis of sexual dimorphism in femoral neck fragility has its origins in growth and aging. J Bone Miner Res. 2003;18:1766–1774.

32. Beck TJ. Measuring the structural strength of bones with dual-energy X-ray absorptiometry: principles, technical limitations, and future possibilities. Osteoporos Int. 2003;14:581–588.

33. Di X, Matsuzaki H, Webster TA, et al. Dynamic model based algorithms for screening and genotyping over 100K SNPs on oligonucleotide microarrays. Bioinformatics. 2005;21:1958–1963.

34. Rabbee N, Speed TP. A genotype calling algorithm for affymetrix SNP arrays. Bioinformatics. 2006;22:7–12.

35. Dixon SC, Horig J, Guo Y, Reed E, Figg WD. Methods for extracting and amplifying genomic DNA isolated from frozen serum. Nat Biotechnol. 1998;16:91–94.

36. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38:909–909.

37. Lencz T, Morgan TV, Athanasiou M, et al. Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry. 2007;12:572–580.

38. Barrett JC, Fry B, Maller J, Daly MJ. Haplview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–265.

39. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet. 2004;74:765–769.

40. Fisher RA. Statistical methods for research workers, 14th ed. New York: Hafner, 1970. (Originally Published: Edinburg: Oliver and Boyd, 1925.)

41. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics. 2000;155:945–955.

42. Filardi S, Zebaze RM, Duan Y, Edmonds J, Beck T, Seeman E. Femoral neck fragility in women has its structural and biomechanical basis established by perioseal modeling during growth and endocortical remodeling during aging. Osteoporos Int. 2004;15:103–107.

43. Beck TJ, Stone KL, Oreskovic TL, et al. Effects of current and discontinued estrogen replacement therapy on hip structural geometry: the Study of Osteoporotic Fractures. J Bone Miner Res. 2001;16:2103–2110.

44. Beck TJ, Oreskovic TL, Stone KL, et al. Structural adaptation to changing skeletal load in the progression toward hip fragility: the Study of Osteoporotic Fractures. J Bone Miner Res. 2001;16:1108–1119.

45. Gluer CC, Cummings SR, Pressman A, et al. Prediction of hip fractures from pelvic radiographs: the Study of Osteoporotic Fractures. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1994;9:671–677.

46. Partanen J, Jamsa T, Jalovaara P. Influence of the upper femur and pelvic geometry on the risk and type of hip fractures. J Bone Miner Res. 2001;16:1540–1546.

47. Beck TJ, Ruff CB, Mourtada FA, et al. Dual-energy X-ray absorptiometry-derived structural geometry for stress fracture prediction in male US Marine Corps recruits. J Bone Miner Res. 1996;11:645–653.

48. Ruff CB. Body size, body shape, and long bone strength in modern humans. J Hum Evol. 2000;38:269–290.

49. Ioannidis JP, Ng MY, Sham PC, et al. Meta-analysis of genome-wide scans provides evidence for sex- and site-specific regulation of bone mass. J Bone Miner Res. 2007;22:173–183.

50. Duncan EL, Brown MA, Sinsheimer J, et al. suggestive linkage of the pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry. 2007;12:572–580.
52. Wilson SG, Reed PW, Bansal A, et al. Comparison of genome screens for two independent cohorts provides replication of suggestive linkage of bone mineral density to 3p21 and 1p36. Am J Hum Genet. 2003;72:144–155.

53. Benes H, Weinstein RS, Zheng W, et al. Chromosomal mapping of osteopenia-associated quantitative trait loci using closely related mouse strains. J Bone Miner Res. 2000;15:626–633.

54. Liu YZ, Wilson SG, Wang L, et al. Identification of PLCL1 gene for hip bone size variation in females in a genome-wide association study. PLoS ONE. 2008;3:e3160.

55. Kiss H, Darai E, Kiss C, et al. Comparative human/murine sequence analysis of the common eliminated region 1 from human 3p21.3. Mamm Genome. 2002;13:646–655.

56. Kiss H, Yang Y, Kiss C, et al. The transcriptional map of the common eliminated region 1 (C3CER1) in 3p21.3. Eur J Hum Genet. 2002;10:52–61.

57. Kholodnyuk ID, Kozireva S, Kost-Alimova M, Kashuba V, Klein G, Imreh S. Downregulation of 3p genes, LTF, SLC38A3, and DRR1, upon growth of human chromosome 3-mouse fibrosarcoma hybrids in severe combined immunodeficiency mice. Int J Cancer. 2006;119:99–107.

58. Saito H, Kubota M, Roberts RW, Chi Q, Matsunami H. RTP family members induce functional expression of mammalian odorant receptors. Cell. 2004;119:679–691.

59. Sorio C, Capelli P, Lissandrini D, et al. Mucinous cystic carcinoma of the pancreas: a unique cell line and xenograft model of a preinvasive lesion. Virchows Arch. 2005;446:239–249.

60. Moore PS, Beghelli S, Zamboni G, Scarpa A. Genetic abnormalities in pancreatic cancer. Mol Cancer 2003;2:7.

61. Tannapfel A, Anhalt K, Hausermann P, et al. Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J Pathol. 2003;201:238–249.

62. Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol. 2003;200:39–46.

63. Wu L, Wu Y, Gathings B, et al. Smad4 as a transcription corepressor for estrogen receptor alpha. J Biol Chem. 2003;278:15192–15200.

64. Matsuda T, Yamamoto T, Muraguchi A, Saatcioglu F. Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. J Biol Chem. 2001;276:42908–42914.

65. Yamamoto T, Saatcioglu F, Matsuda T. Cross-talk between bone morphogenetic proteins and estrogen receptor signaling. Endocrinology. 2002;143:2635–2642.

66. Linkhart TA, Mohan S, Baylink DJ. Growth factors for bone growth and repair: IGF, TGF-β, and BMP. Bone. 1996;19:15–12S.

67. Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23:279–302.

68. Sakou T, Onishi T, Yamamoto T, Nagamine T, Sampath T, Ten DP. Localization of Smads, the TGF-β family intracellular signaling components during endochondral ossification. J Bone Miner Res. 1999;14:1145–1152.

69. Zhang J, Tan X, Li W, et al. Smad4 is required for the normal organization of the cartilage growth plate. Dev Biol. 2005;284:311–322.

70. Yu Y, Bliss JP, Bruce WJ, Walsh WR. Bone morphogenetic proteins and Smad expression in ovine tendon-bone healing. Arthroscopy. 2007;23:205–210.

71. Farhadieh RD, Gianoutsos MP, Yu Y, Walsh WR. The role of bone morphogenetic proteins BMP-2 and BMP-4 and their related post-receptor signaling system (Smads) in distraction osteogenesis of the mandible. J Craniofac Surg. 2004;15:714–718.

72. Alvarez J, Serra R. Unique and redundant roles of Smad3 in TGF-β-mediated regulation of long bone development in organ culture. Dev Dyn. 2004;230:685–699.

73. Luciano M, Lind PA, Deary IJ, et al. Testing replication of a 5-SNP set for general cognitive ability in six population samples. Eur J Hum Genet. 2008;16:1025.

74. Houlston RS, Webb E, Broderick P, et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet. 2008;40:1426–1435.

75. Zeggini E, Scott LJ, Saxena R, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet. 2008;40:638–645.

76. Beck TJ, Ruff CB, Warden KE, Scott WW Jr, Rao GU. Predicting femoral neck strength from bone mineral data: a structural approach. Invest Radiol. 1990;25:6–18.

GENOME-WIDE STUDY OF FEMORAL NECK BONE GEOMETRY